

# Myelodysplastic Syndrome-India Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M6DC07AF630MEN.html>

Date: May 2018

Pages: 142

Price: US\$ 2,980.00 (Single User License)

ID: M6DC07AF630MEN

## Abstracts

### Report Summary

Myelodysplastic Syndrome-India Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myelodysplastic Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole India and Regional Market Size of Myelodysplastic Syndrome 2013-2017, and development forecast 2018-2023

Main market players of Myelodysplastic Syndrome in India, with company and product introduction, position in the Myelodysplastic Syndrome market

Market status and development trend of Myelodysplastic Syndrome by types and applications

Cost and profit status of Myelodysplastic Syndrome, and marketing status

Market growth drivers and challenges

The report segments the India Myelodysplastic Syndrome market as:

India Myelodysplastic Syndrome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North India

Northeast India

East India

South India

## West India

India Myelodysplastic Syndrome Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alkylating Agents  
Cytotoxic Antibiotics  
Topoisomerase Inhibitors  
Others

India Myelodysplastic Syndrome Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic

India Myelodysplastic Syndrome Market: Players Segment Analysis (Company and Product introduction, Myelodysplastic Syndrome Sales Volume, Revenue, Price and Gross Margin):

Celgene  
Novartis  
Otsuka  
Actinium Pharmaceuticals  
Accelaron Pharma  
Bellicum Pharmaceuticals  
Cornerstone Pharmaceuticals  
CTI BioPharma  
Onconova Therapeutics  
Strategia Therapeutics  
KaloBios Pharmaceuticals  
Kiadis Pharma  
Mirati Therapeutics  
Astex  
Celator Pharmaceuticals  
Eli-lilly  
Sunesis Pharmaceuticals  
Targazyme  
Gamida Cell

GlaxoSmithKline  
Sumitomo Dainippon Pharma  
TetraLogic Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF MYELOYDYSPLASTIC SYNDROME**

- 1.1 Definition of Myelodysplastic Syndrome in This Report
- 1.2 Commercial Types of Myelodysplastic Syndrome
  - 1.2.1 Alkylating Agents
  - 1.2.2 Cytotoxic Antibiotics
  - 1.2.3 Topoisomerase Inhibitors
  - 1.2.4 Others
- 1.3 Downstream Application of Myelodysplastic Syndrome
  - 1.3.1 Hospital
  - 1.3.2 Clinic
- 1.4 Development History of Myelodysplastic Syndrome
- 1.5 Market Status and Trend of Myelodysplastic Syndrome 2013-2023
  - 1.5.1 United States Myelodysplastic Syndrome Market Status and Trend 2013-2023
  - 1.5.2 Regional Myelodysplastic Syndrome Market Status and Trend 2013-2023

### **CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Myelodysplastic Syndrome in United States 2013-2017
- 2.2 Consumption Market of Myelodysplastic Syndrome in United States by Regions
  - 2.2.1 Consumption Volume of Myelodysplastic Syndrome in United States by Regions
  - 2.2.2 Revenue of Myelodysplastic Syndrome in United States by Regions
- 2.3 Market Analysis of Myelodysplastic Syndrome in United States by Regions
  - 2.3.1 Market Analysis of Myelodysplastic Syndrome in New England 2013-2017
  - 2.3.2 Market Analysis of Myelodysplastic Syndrome in The Middle Atlantic 2013-2017
  - 2.3.3 Market Analysis of Myelodysplastic Syndrome in The Midwest 2013-2017
  - 2.3.4 Market Analysis of Myelodysplastic Syndrome in The West 2013-2017
  - 2.3.5 Market Analysis of Myelodysplastic Syndrome in The South 2013-2017
  - 2.3.6 Market Analysis of Myelodysplastic Syndrome in Southwest 2013-2017
- 2.4 Market Development Forecast of Myelodysplastic Syndrome in United States 2018-2023
  - 2.4.1 Market Development Forecast of Myelodysplastic Syndrome in United States 2018-2023
  - 2.4.2 Market Development Forecast of Myelodysplastic Syndrome by Regions 2018-2023

### **CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Myelodysplastic Syndrome in United States by Types

3.1.2 Revenue of Myelodysplastic Syndrome in United States by Types

### 3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

### 3.3 Market Forecast of Myelodysplastic Syndrome in United States by Types

## **CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Myelodysplastic Syndrome in United States by Downstream Industry

### 4.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Major Countries

4.2.1 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in New England

4.2.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in The Midwest

4.2.4 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in The West

4.2.5 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in The South

4.2.6 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Southwest

### 4.3 Market Forecast of Myelodysplastic Syndrome in United States by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MYELODYSPLASTIC SYNDROME**

### 5.1 United States Economy Situation and Trend Overview

## 5.2 Myelodysplastic Syndrome Downstream Industry Situation and Trend Overview

### **CHAPTER 6 MYELOYDYSPLASTIC SYNDROME MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES**

#### 6.1 Sales Volume of Myelodysplastic Syndrome in United States by Major Players

#### 6.2 Revenue of Myelodysplastic Syndrome in United States by Major Players

#### 6.3 Basic Information of Myelodysplastic Syndrome by Major Players

##### 6.3.1 Headquarters Location and Established Time of Myelodysplastic Syndrome Major Players

##### 6.3.2 Employees and Revenue Level of Myelodysplastic Syndrome Major Players

#### 6.4 Market Competition News and Trend

##### 6.4.1 Merger, Consolidation or Acquisition News

##### 6.4.2 Investment or Disinvestment News

##### 6.4.3 New Product Development and Launch

### **CHAPTER 7 MYELOYDYSPLASTIC SYNDROME MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

#### 7.1 Celgene

##### 7.1.1 Company profile

##### 7.1.2 Representative Myelodysplastic Syndrome Product

##### 7.1.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celgene

#### 7.2 Novartis

##### 7.2.1 Company profile

##### 7.2.2 Representative Myelodysplastic Syndrome Product

##### 7.2.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Novartis

#### 7.3 Otsuka

##### 7.3.1 Company profile

##### 7.3.2 Representative Myelodysplastic Syndrome Product

##### 7.3.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Otsuka

#### 7.4 Actinium Pharmaceuticals

##### 7.4.1 Company profile

##### 7.4.2 Representative Myelodysplastic Syndrome Product

##### 7.4.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Actinium Pharmaceuticals

#### 7.5 Acceleron Pharma

##### 7.5.1 Company profile

##### 7.5.2 Representative Myelodysplastic Syndrome Product

7.5.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Acceleron Pharma

7.6 Bellicum Pharmaceuticals

7.6.1 Company profile

7.6.2 Representative Myelodysplastic Syndrome Product

7.6.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Bellicum Pharmaceuticals

7.7 Cornerstone Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Myelodysplastic Syndrome Product

7.7.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals

7.8 CTI BioPharma

7.8.1 Company profile

7.8.2 Representative Myelodysplastic Syndrome Product

7.8.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of CTI BioPharma

7.9 Onconova Therapeutics

7.9.1 Company profile

7.9.2 Representative Myelodysplastic Syndrome Product

7.9.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Onconova Therapeutics

7.10 Strategia Therapeutics

7.10.1 Company profile

7.10.2 Representative Myelodysplastic Syndrome Product

7.10.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Strategia Therapeutics

7.11 KaloBios Pharmaceuticals

7.11.1 Company profile

7.11.2 Representative Myelodysplastic Syndrome Product

7.11.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of KaloBios Pharmaceuticals

7.12 Kiadis Pharma

7.12.1 Company profile

7.12.2 Representative Myelodysplastic Syndrome Product

7.12.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Kiadis Pharma

7.13 Mirati Therapeutics

7.13.1 Company profile

- 7.13.2 Representative Myelodysplastic Syndrome Product
- 7.13.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Mirati Therapeutics
- 7.14 Astex
  - 7.14.1 Company profile
  - 7.14.2 Representative Myelodysplastic Syndrome Product
  - 7.14.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Astex
- 7.15 Celator Pharmaceuticals
  - 7.15.1 Company profile
  - 7.15.2 Representative Myelodysplastic Syndrome Product
  - 7.15.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celator Pharmaceuticals
- 7.16 Eli-lilly
- 7.17 Sunesis Pharmaceuticals
- 7.18 Targazyme
- 7.19 Gamida Cell
- 7.20 GlaxoSmithKline
- 7.21 Sumitomo Dainippon Pharma
- 7.22 TetraLogic Pharmaceuticals

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 8.1 Industry Chain of Myelodysplastic Syndrome
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 9.1 Cost Structure Analysis of Myelodysplastic Syndrome
- 9.2 Raw Materials Cost Analysis of Myelodysplastic Syndrome
- 9.3 Labor Cost Analysis of Myelodysplastic Syndrome
- 9.4 Manufacturing Expenses Analysis of Myelodysplastic Syndrome

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 10.1 Marketing Channel



- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Myelodysplastic Syndrome-India Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M6DC07AF630MEN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M6DC07AF630MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970